Who Gets Lacosamide-Induced Arrhythmias?
Lacosamide, an antiepileptic drug used for partial-onset seizures, can cause cardiac arrhythmias like bradycardia, AV block, or atrial fibrillation, mainly in patients with underlying heart conditions such as conduction disorders, heart failure, or prior myocardial infarction. Risk rises with higher doses (above 400 mg/day), IV administration, or concurrent use of drugs that prolong PR interval (e.g., beta-blockers, calcium channel blockers).[1][2]
Baseline Cardiac Screening Before Starting
Perform ECG to check PR interval, QRS duration, and QTc before initiation, especially in patients over 65 or with cardiac history. Baseline PR >200 ms or QRS >120 ms warrants caution or avoidance. Monitor sodium levels, as hyponatremia exacerbates risks.[3][4]
Dose Adjustments and Administration Tips
Start at low doses (50-100 mg/day orally) and titrate slowly (add 100 mg/week) to minimize cardiac effects. Cap total dose at 400 mg/day for most; use even lower (200-300 mg) in renal/hepatic impairment. Prefer oral over IV when possible—IV slows infusion rate to 60 min for 200 mg doses to reduce peak plasma spikes.[1][5]
Ongoing ECG Monitoring Protocol
Repeat ECG at 1 week, then monthly for first 3 months, or sooner if symptoms like dizziness, syncope, or palpitations appear. Target PR <220 ms and QRS <140 ms; discontinue if PR prolongs >25% from baseline or exceeds 240 ms.[2][3]
Drug Interactions to Avoid or Watch
Steer clear of QT-prolonging agents (e.g., amiodarone, ondansetron) or sodium channel blockers (e.g., carbamazepine). Adjust doses with CYP2C19 inhibitors/inducers. Common culprits include digoxin or verapamil—in these cases, prioritize alternatives like levetiracetam.[4][6]
What to Do If Symptoms Emerge
Stop lacosamide immediately for second-degree AV block, atrial flutter/fibrillation, or ventricular tachycardia. Temporary pacing may be needed; most resolve after discontinuation. Report via FDA MedWatch for tracking.[1][5]
Safer Alternatives for At-Risk Patients
Switch to broad-spectrum AEDs like lamotrigine, valproate, or levetiracetam, which have lower cardiac risk profiles. Brivaracetam offers similar efficacy to lacosamide with less PR prolongation.[6][7]
[1]: Lacosamide Prescribing Information (Vimpat), UCB, 2023
[2]: Epilepsia. Lacosamide cardiac safety review, 2019
[3]: AAN/AES Guideline on AED cardiac monitoring, 2020
[4]: Drugs.com Lacosamide Interactions
[5]: FDA Adverse Event Reporting, Lacosamide
[6]: Neurology. Comparative AED cardiac risks, 2021
[7]: Brivaracetam vs Lacosamide Trial, Lancet Neurol 2022